Scribd Logo
Upload

Welcome to Scribd!

  • Prezentare FFF Noua Cu Patologii Prin Anomalii Ale Sist Complement

    Uploaded by

    Denisa Carmen Coliof
    17 views38 pages
    The document outlines ongoing clinical trials investigating complement-blocking agents for treating complement-mediated kidney diseases like C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), and IgA nephropathy (IgAN). It describes phase 2 trials of avacopan, pegcetacoplan, and iptacopan for C3G that showed reductions in proteinuria, improvements in eGFR, and stabilization of kidney function. Phase 3 trials are currently recruiting for pegcetacoplan and iptacopan in C3G. Eculizumab phase 2 trials demonstrated reductions in hematuria and proteinuria in aHUS patients. Narsoplimab

    Original Description:

    Original Title

    Prezentare Fff Noua Cu Patologii Prin Anomalii Ale Sist Complement

    Copyright

    © © All Rights Reserved

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    The document outlines ongoing clinical trials investigating complement-blocking agents for treating complement-mediated kidney diseases like C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), and IgA nephropathy (IgAN). It describes phase 2 trials of avacopan, pegcetacoplan, and iptacopan for C3G that showed reductions in proteinuria, improvements in eGFR, and stabilization of kidney function. Phase 3 trials are currently recruiting for pegcetacoplan and iptacopan in C3G. Eculizumab phase 2 trials demonstrated reductions in hematuria and proteinuria in aHUS patients. Narsoplimab

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    17 views38 pages

    Prezentare FFF Noua Cu Patologii Prin Anomalii Ale Sist Complement

    Uploaded by

    Denisa Carmen Coliof
    The document outlines ongoing clinical trials investigating complement-blocking agents for treating complement-mediated kidney diseases like C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), and IgA nephropathy (IgAN). It describes phase 2 trials of avacopan, pegcetacoplan, and iptacopan for C3G that showed reductions in proteinuria, improvements in eGFR, and stabilization of kidney function. Phase 3 trials are currently recruiting for pegcetacoplan and iptacopan in C3G. Eculizumab phase 2 trials demonstrated reductions in hematuria and proteinuria in aHUS patients. Narsoplimab

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 38

    Outline

    C3G
    Challenges With Current Treatments
    aHUS
    Challenges With Current Treatments
    IgAN
    Challenges With Current Treatments
    IgAN
    Challenges With Current Treatments (cont)
    Renal Transplantation
    C3G and aHUS
    Renal Transplantation
    IgAN
    The Complement Activation Pathways
    The Role of Complement in Glomerular
    Diseases
    C3G, IgAN, aHUS
    Pathogenesis of the C3 Glomerulopathies
    Reclassification of MPGN
    Understanding the Pathogenesis of C3-
    Dominant GN
    Understanding the Pathogenesis of aHUS
    Understanding the Pathogenesis of IgAN
    IgAN
    The Multi-Hits Pathogenesis Model
    Complement Blocking Agents
    How Can These New Agents Address Unmet
    Medical Needs?
    Complement-Mediated Kidney Diseases
    Latest Clinical Data
    C3G
    Avacopan Phase 2 - Rationale for Use
    C3G
    Avacopan Phase 2 - Study Design
    C3G
    Avacopan Phase 2 - Results
    C3G
    Avacopan Phase 2 - Results (cont)
    C3G
    Avacopan Phase 2 - Results (cont)
    C3G
    Pegcetacoplan Phase 2 - Study Design
    C3G
    Pegcetacoplan Phase 2 - Results
    C3G
    Pegcetacoplan Phase 3 - Study Design (Currently
    Recruiting)
    C3G
    Iptacopan Phase 2
    C3G
    Iptacopan Phase 3 - Study Design (Currently
    Recruiting)
    aHUS
    Eculizumab Phase 2 - Study Design
    aHUS
    Eculizumab Phase 2 - Results
    aHUS
    Eculizumab Phase 2 - Safety Results
    IgAN
    Narsoplimab Phase 2 - Study Design
    IgAN
    Narsoplimab Phase 2 - Results
    IgAN
    Iptacopan Phase 2 – Rationale For Use
    IgAN
    Iptacopan Phase 2 - Study Design
    IgAN
    Iptacopan Phase 2 - Results
    Conclusion

    You might also like